首页> 外文期刊>Sleep & breathing =: Schlaf & Atmung >Metoprolol has a similar therapeutic effect as amlodipine on BP lowering in hypertensive patients with obstructive sleep apnea
【24h】

Metoprolol has a similar therapeutic effect as amlodipine on BP lowering in hypertensive patients with obstructive sleep apnea

机译:美托洛尔在高血压睡眠呼吸暂停的高血压患者中具有类似的治疗效果,作为氨氯氨阶对高血压患者的BP降低

获取原文
获取原文并翻译 | 示例
           

摘要

sPurpose-Blocker use has been controversial for a long time in the management of hypertensive patients with obstructive sleep apnea (OSA). The aim of present study was to compare the effects of metoprolol on BP lowering with amlodipine in hypertensive OSA patients.MethodsHypertensive subjects with OSA were randomly assigned to metoprolol and amlodipine groups, receiving 12weeks of oral either metoprolol (47.5mg once daily) or amlodipine (5mg once daily) treatment. At baseline and after the 12-week treatment period, 24-h ambulatory blood pressure monitoring was performed in both groups.ResultsBoth of metoprolol and amlodipine treatments significantly lowered 24-h blood pressure (BP) (from 143/88 to 132.3/81.6mmHg; from 141.3/84.5 to 133.7/80.8mmHg), daytime BP (from 146/90.2 to 136.4/84.6mmHg; from 145.1/87.6 to 138.2/84.1mmHg), and nighttime BP (from 139.1/83.9 to 125.7/76.2mmHg; from 134.5/78.5 to 125.8/74.1mmHg) (all P 0.05). Besides, metoprolol significantly reduced daytime heart rate (HR) (P 0.05).ConclusionsMetoprolol had similar therapeutic effects on BP lowering as amlodipine and could not decrease HR during the nighttime in hypertensive patients with OSA.
机译:烟雾阻滞剂使用很长时间在患有阻塞性睡眠呼吸暂停(OSA)的高血压患者的管理中存在争议。目前研究的目的是比较氟洛尔洛尔对高血压OSA患者中氨氯普林降低的BP降低的影响。用OSA随机分配给氟洛尔洛尔和氨氯唑啉基团,接受12周的口服甲酚(每日47.5mg)或氨氯地升(每日5mg)治疗。在基线和12周治疗期后,在两组中进行24-h动态血压监测。氟托洛尔和氨氯替洛尼治疗的方法显着降低了24小时血压(BP)(从143/88至132.3 / 81.6mmHg ;从141.3 / 84.5到133.7 / 80.8mmhg),白天bp(从146 / 90.2到136.4 / 84.6mmhg;从145.1 / 87.6到138.2 / 84.1mmg)和夜间BP(从139.1 / 83.9到125.7 / 76.2mmhg;从134.5 / 78.5到125.8 / 74.1mmg)(所有p 0.05)。此外,美托洛尔显着降低了白天心率(HR)(P 0.05)。ConclusionsmetOmetOlol对Bp降低的同性恋效果类似,并且在OSA高血压患者的夜间中不能降低HR。

著录项

  • 来源
  • 作者单位

    Harbin Med Univ Affiliated Hosp 1 Cardiovasc Dept Harbin Heilongjiang Peoples R China;

    Harbin Med Univ Affiliated Hosp 1 Cardiovasc Dept Harbin Heilongjiang Peoples R China;

    Harbin Med Univ Affiliated Hosp 1 Cardiovasc Dept Harbin Heilongjiang Peoples R China;

    Harbin Med Univ Affiliated Hosp 1 Cardiovasc Dept Harbin Heilongjiang Peoples R China;

    Harbin Med Univ Affiliated Hosp 1 Cardiovasc Dept Harbin Heilongjiang Peoples R China;

    Harbin Med Univ Affiliated Hosp 1 Cardiovasc Dept Harbin Heilongjiang Peoples R China;

    Harbin Med Univ Affiliated Hosp 1 Cardiovasc Dept Harbin Heilongjiang Peoples R China;

    Harbin Med Univ Affiliated Hosp 1 Cardiovasc Dept Harbin Heilongjiang Peoples R China;

    Harbin Med Univ Affiliated Hosp 1 Cardiovasc Dept Harbin Heilongjiang Peoples R China;

    Harbin Med Univ Affiliated Hosp 1 Cardiovasc Dept Harbin Heilongjiang Peoples R China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 呼吸系及胸部疾病;
  • 关键词

    (1)-Blockers; Calcium channel blockers; Obstructive sleep apnea; Hypertension; Blood pressure;

    机译:(1) - 伯克斯;钙通道阻滞剂;阻塞性睡眠呼吸暂停;高血压;血压;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号